Gene · 4751
Papers2,227
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 2,227
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Overexpressed NEK2 contributes to progression and cisplatin resistance through activating the Wnt/β-catenin signaling pathway in cervical cancer. | Cancer Cell Int | 2025 | 39953509 | PubTator, text mining | PubMed |
| Stem cells (neoblasts) and positional information jointly dominate regeneration in planarians. | Heliyon | 2025 | 39877626 | PubTator, text mining | PubMed |
| Identification of Immune Infiltration-Associated CC Motif Chemokine Ligands as Biomarkers and Targets for Colorectal Cancer Prevention and Immunotherapy. | Int J Mol Sci | 2025 | 39859340 | PubTator, text mining | PubMed |
| Insights into NEK2 inhibitors as antitumor agents: From mechanisms to potential therapeutics. | Eur J Med Chem | 2025 | 39832390 | PubTator, text mining | PubMed |
| Targeting the mitotic kinase NEK2 enhances CDK4/6 inhibitor efficacy by potentiating genome instability. | J Biol Chem | 2025 | 39826695 | PubTator, text mining | PubMed |
| Phosphoproteomics guides low dose drug combination of cisplatin and silmitasertib against concurrent chemoradiation resistant cervical cancer. | Mol Omics | 2025 | 39665434 | PubTator, text mining | PubMed |
| NEK2 Promotes ESCC Malignant Progression by Inhibiting Cellular Senescence via the FOXM1/c-Myc/p27 Signaling Pathway. | Mol Carcinog | 2025 | 39503194 | PubTator, text mining | PubMed |
| NEK2 promotes colorectal cancer progression by activating the TGF-β/Smad2 signaling pathway. | Transl Oncol | 2025 | 39499996 | PubTator, text mining | PubMed |
| Role of NEK2 in tumorigenesis and tumor progression. | Trends Mol Med | 2025 | 39181803 | PubTator, text mining | PubMed |
| NEK2 affects the ferroptosis sensitivity of gastric cancer cells by regulating the expression of HMOX1 through Keap1/Nrf2. | Mol Cell Biochem | 2025 | 38503948 | PubTator, text mining | PubMed |
| Decoding oral cancer: insights from miRNA expression profiles and their regulatory targets. | Front Mol Biosci | 2024 | 39935706 | PubTator, text mining | PubMed |
| NEK2 Phosphorylates RhoGDI1 to Promote Cell Proliferation, Migration and Invasion Through the Activation of RhoA and Rac1 in Colon Cancer Cells. | Cells | 2024 | 39768163 | PubTator, text mining | PubMed |
| NUF2 is associated with cancer stem cell characteristics and a potential drug target for prostate cancer. | Front Mol Biosci | 2024 | 39703688 | PubTator, text mining | PubMed |
| A scoring model based on bacterial lipopolysaccharide-related genes to predict prognosis in NSCLC. | Front Genet | 2024 | 39610830 | PubTator, text mining | PubMed |
| Identification of Crucial Cancer Stem Cell Genes Linked to Immune Cell Infiltration and Survival in Hepatocellular Carcinoma. | Int J Mol Sci | 2024 | 39596041 | PubTator, text mining | PubMed |
| Structural and Functional Insights into Dishevelled-Mediated Wnt Signaling. | Cells | 2024 | 39594618 | PubTator, text mining | PubMed |
| Mesenchymal stem cell-derived exosomes carrying miR-486-5p inhibit glycolysis and cell stemness in colorectal cancer by targeting NEK2. | BMC Cancer | 2024 | 39506654 | PubTator, text mining | PubMed |
| NEK2 is a potential pan-cancer biomarker and immunotherapy target. | Discov Oncol | 2024 | 39505744 | PubTator, text mining | PubMed |
| Unveiling novel prognostic biomarkers and therapeutic targets for HBV-associated hepatocellular carcinoma through integrated bioinformatic analysis. | Medicine (Baltimore) | 2024 | 39470543 | PubTator, text mining | PubMed |
| METTL3 facilitates the progression of cervical cancer by m6A modification-mediated up-regulation of NEK2. | Sci Rep | 2024 | 39424828 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4751/papers?page=5